Navigation Links
Could the Spanish flu devastate us again?
Date:8/15/2011

The last century has seen two major pandemics caused by the H1N1 virus the Spanish Flu in 1918 and 2009's Swine Flu scare, which had thousands travelling with surgical masks and clamoring for vaccination. But scientists did not know what distinguished the Swine Flu from ordinary influenza in pigs or seasonal outbreaks in humans, giving it the power to travel extensively and infect large populations.

Until now. Prof. Nir Ben-Tal of Tel Aviv University's Department of Biochemistry and Molecular Biology and his graduate student Daphna Meroz, in collaboration with Dr. Tomer Hertz of Seattle's Fred Hutchinson Cancer Research Center, have developed a unique computational method to address this question. Published in the journal PNAS, the research presents a valuable tool for identifying viral mutation strategies, tracking various virus strains and developing vaccinations and anti-virals which can protect the population. It may also lead to more precisely designed vaccines to combat these viral mutations.

Their method reveals that mutations in the virus' amino acids in specific positions, such as antigenic receptor sites, may explain how the new strain successfully spread throughout the population in 2009. These alterations allowed the strain to evade both existing vaccines and the immune system's defenses.

Playing a game of cat and mouse

Viruses and our immune systems are constantly at war. A virus constantly mutates to escape notice, and our immune system strives to play catch-up to recognize the virus and mobilize the body's defense system.

To determine the spread of the 2009 human pandemic flu, Prof. Ben-Tal and his fellow researchers analyzed the hemagglutinin protein, which controls the virus' ability to fuse to a host cell in the body and transfer the genome which contains the information needed to make more virus. Eventually, he says, our immune system is able to recognize a virus' hemagglutinin, which triggers its reaction to fight against the virus.

Using a statistical learning algorithm, the researchers compared amino acid positions in the 2009 strain of H1N1 against the common flu and the strain of H1N1 found in Swine Flu, and discovered that major sequence changes that had occurred, altering antigenic sites and severely compromising the immune system's ability to recognize and react to the virus.

"Our new computation method showed that the main differences between the pandemic strain and the common seasonal H1N1 strain are in some 10 amino acid positions," Prof. Ben-Tal and Meroz report. "That's all it takes."

Experiments conducted by Sun-Woo Yoon, Dr. Mariette F. Ducatez and, Thomas P. Fabrizio from Prof. Richard J. Webby's lab at St. Jude Children's Research Hospital in Memphis, TN, confirmed some of the theoretical predictions.

Predicting pandemic

Like its 1918 predecessor the Spanish Flu, the 2009 pandemic flu will likely go into "hibernation" now that this particular strain has been recognized by the immune system, its power to infect has been compromised. But we were lucky: despite the relatively low death toll of the pandemic in 2009, similar to the number of deaths attributable to common seasonal flu, we might be facing more dangerous future outbreaks of mutated H1N1 varieties.

Because of the enormous mutation rate, says Prof. Ben-Tal, viruses can spread widely and rapidly, and vaccines are fairly inefficient. In the future, a refined version of this computational method may ultimately be used to generically compare various strains of viruses. This in-depth analysis might lead to the ability to predict how a strain will morph and determine if a pandemic could strike.

This is an important step towards revealing the amino acid determinants of the emergence of flu pandemics, but there is more work to be done, the researchers say.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert

Related biology news :

1. Increased tropical forest growth could release carbon from the soil
2. Higher estrogen production in the breast could confer greater cancer risk than thought
3. New technology could capture ammonia from liquid manure
4. Cancer biomarker -- detectable by blood test -- could improve prostate cancer detection
5. Wearable device that vibrates fingertip could improve ones sense of touch
6. Finding could reduce antibiotic use in critically ill patients
7. Crop breeding could slash CO2 levels
8. Columbia engineering innovative hand-held lab-on-a-chip could streamline blood testing worldwide
9. Warming climate could give exotic grasses edge over natives
10. Getting 50-year-old Americans as healthy as Europeans could save Medicare and Medicaid $632 billion by 2050
11. Could patients own kidney cells cure kidney disease?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: